Medical device company Creo Medical Group PLC said Wednesday that it entered into a distribution agreement with Diagmed Healthcare Ltd.
Under the terms of the agreement, the two companies will collaborate for 18 months to distribute Creo’s CROMA energy platform and Speedboat products, targeting endoscopist minimally invasive surgery, on the UK market.
“In line with Creo’s education led commercial strategy, Diagmed will also advance the roll out of Creo’s Clinical Education Programme in the UK, to ensure quality control and best patient outcomes through the education of key clinicians in the use of Speedboat and the CROMA platform, the company said.
After the initial 18-month phase, the two companies will sign another deal making Diagmed Creo’s sole distributor for the CROMA advanced energy electrosurgery platform, the company said.
